← FDA DRUG APPROVALS

FDA NDA · NDA022334

AFINITOR

everolimus

Sponsor: NOVARTIS

APPLICATION
NDA022334
TYPE
NDA
ORIGINAL APPROVAL
2009-03-30
LATEST ACTION
2026-06-01
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

AFINITOR · ReferencePrescription
EVEROLIMUS 7.5MG · TABLET · ORAL
AFINITOR · ReferencePrescription
EVEROLIMUS 10MG · TABLET · ORAL
AFINITOR · ReferencePrescription
EVEROLIMUS 2.5MG · TABLET · ORAL
AFINITOR · ReferencePrescription
EVEROLIMUS 5MG · TABLET · ORAL

Approval history

2026-06-01Labeling · Supplement 55 · standardLabelAP
2022-02-01Labeling · Supplement 51 · standardLetterAP
2021-12-30Efficacy · Supplement 50 · standardLabelAP
2021-04-16Labeling · Supplement 47 · standardLabelAP
2020-02-13Labeling · Supplement 44 · standardLabelAP
2020-01-22Labeling · Supplement 45 · standardLetterAP
2018-04-10Efficacy · Supplement 40 · standardLabelAP
2017-09-26Efficacy · Supplement 39 · standardLabelAP
2016-06-14Labeling · Supplement 38 · standardLabelAP
2016-02-26Efficacy · Supplement 36 · priorityLetterAP
2016-02-18Efficacy · Supplement 35 · priorityLetterAP
2016-02-04Labeling · Supplement 34 · standardLabelAP
2016-01-29Efficacy · Supplement 32 · standardLetterAP
2015-09-18Efficacy · Supplement 31 · standardLetterAP
2015-05-22Efficacy · Supplement 30 · standardLabelAP
2015-01-23Labeling · Supplement 29 · standardLetterAP
2014-12-18Efficacy · Supplement 27 · standardLabelAP
2014-10-20Manufacturing (CMC) · Supplement 28 · priorityAP
2014-09-12Manufacturing (CMC) · Supplement 26 · priorityAP
2014-07-01Labeling · Supplement 25 · standardLetterAP
2014-02-20Labeling · Supplement 21 · standardLabelAP
2014-02-20Labeling · Supplement 24 · standardLabelAP
2014-02-20Labeling · Supplement 23 · standardLabelAP
2013-11-06Efficacy · Supplement 22 · standardLetterAP
2013-06-21Manufacturing (CMC) · Supplement 20 · priorityAP
2013-03-26Manufacturing (CMC) · Supplement 19 · priorityAP
2012-08-29Labeling · Supplement 18 · standardLetterAP
2012-07-20Efficacy · Supplement 16 · standardLabelAP
2012-04-26Efficacy · Supplement 17 · priorityLabelAP
2012-03-30Efficacy · Supplement 14 · standardLabelAP
2012-03-30Labeling · Supplement 15 · unknownLabelAP
2011-05-05Labeling · Supplement 10 · unknownLabelAP
2011-05-05Efficacy · Supplement 9 · priorityLetterAP
2010-10-29Efficacy · Supplement 6 · priorityLetterAP
2010-07-09Labeling · Supplement 4 · unknownLetterAP
2010-07-09Manufacturing (CMC) · Supplement 5AP
2010-05-13Labeling · Supplement 1 · unknownLabelAP
2009-03-30Type 1 - New Molecular Entity · Original · priorityPediatric Written RequestAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →